Tysabri (natalizumab) is a brand-name intravenous (IV) infusion. It’s prescribed for adults with Crohn’s disease or certain forms of multiple sclerosis. Tysabri has interactions with some ...

Regulators in the US and Europe have started to review Novartis' biosimilar version of Biogen's big-selling multiple sclerosis therapy Tysabri, which could reach the market next year. If approved ...

Polpharma Biologics has become the first company to file for approval in the EU of a biosimilar version of Biogen's blockbuster multiple sclerosis therapy Tysabri. The biotech – headquartered in ...